Company Description
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
| Country | United States |
| Founded | 2018 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Yu-Hsin Lin |
Contact Details
Address: 12750 High Bluff Drive, Suite 475 San Diego, California 92130 United States | |
| Phone | 858 246 6240 |
| Website | belitebio.com |
Stock Details
| Ticker Symbol | BLTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001889109 |
| CUSIP Number | 07782B104 |
| ISIN Number | US07782B1044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors and Chief Executive Officer |
| Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer and Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer and Member of Ophthalmology Clinical Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 20, 2024 | 144 | Filing |
| Nov 19, 2024 | 144 | Filing |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | 144/A | Filing |
| Oct 8, 2024 | 144/A | Filing |
| Oct 3, 2024 | 144 | Filing |
| Oct 3, 2024 | 144 | Filing |
| Oct 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Sep 20, 2024 | 144 | Filing |